Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 19, 2010 - Issue 9
Submit an article Journal homepage
682
Views
222
CrossRef citations to date
0
Altmetric
Reviews

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

Paul A Marks Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Cell Biology and Genetics Program, 1275 York Ave, New York, NY 10065, USA [email protected]
Pages 1049-1066 | Published online: 05 Aug 2010

Citations (222)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (16)

Wenqi Wang, Daoquan Fang, Hao Zhang, Jiao Xue, Drugyel Wangchuk, Jimei Du & Lei Jiang. (2020) Sodium Butyrate Selectively Kills Cancer Cells and Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1. OncoTargets and Therapy 13, pages 4691-4704.
Read now
Bolun Wang, Hui Lyu, Shanshan Pei, Deye Song, Jiangdong Ni & Bolin Liu. (2018) Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle 17:8, pages 985-996.
Read now
Susmitha Apuri & Lubomir Sokol. (2016) An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Investigational Drugs 25:6, pages 687-696.
Read now
Wenxiu Qi, Wenbo Zhang, Holly Edwards, Roland Chu, Gerard J Madlambayan, Jeffrey W Taub, Zhihong Wang, Yue Wang, Chunhuai Li, Hai Lin & Yubin Ge. (2015) Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biology & Therapy 16:12, pages 1784-1793.
Read now
Jenny Y Y Ooi, Natasha K Tuano, Haloom Rafehi, Xiao-Ming Gao, Mark Ziemann, Xiao-Jun Du & Assam El-Osta. (2015) HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes . Epigenetics 10:5, pages 418-430.
Read now
Ahmed Sawas & Owen A O’Connor. (2015) Belinostat for the treatment of T-cell lymphoma. Expert Opinion on Orphan Drugs 3:2, pages 219-227.
Read now
Andrey Poleshko, Andrew V Kossenkov, Natalia Shalginskikh, Anna Pecherskaya, Anna Pecherskaya, Margret B Einarson, Margret B Einarson, Anna Marie Skalka, Anna Marie Skalka, Richard A Katz & Richard A Katz. (2014) Human factors and pathways essential for mediating epigenetic gene silencing. Epigenetics 9:9, pages 1280-1289.
Read now
Ramón Cacabelos & Clara Torrellas. (2014) Epigenetic drug discovery for Alzheimer’s disease. Expert Opinion on Drug Discovery 9:9, pages 1059-1086.
Read now
Gopalan Balasubramanian, Narasimhan Kilambi, Suresh Rathinasamy, Praveen Rajendran, Shridhar Narayanan & Sridharan Rajagopal. (2014) Quinolone-based HDAC inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 29:4, pages 555-562.
Read now
Sergio Valente & Antonello Mai. (2014) Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013). Expert Opinion on Therapeutic Patents 24:4, pages 401-415.
Read now
MarianaS. Gerova & OgnyanI. Petrov. (2014) A Convenient Synthesis of the New Histone Deacetylase Inhibitor Scriptaid. Organic Preparations and Procedures International 46:1, pages 76-79.
Read now
Katherine Ververis, Alison Hiong, Tom C Karagiannis & Paul V Licciardi. (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics: Targets and Therapy 7, pages 47-60.
Read now
Syed F Zafar, Ganji Purnachandra Nagaraju & Bassel El-Rayes. (2012) Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. Expert Opinion on Therapeutic Targets 16:7, pages 707-718.
Read now
Wajana L. Labisso, Matthias Wirth, Natasa Stojanovic, Roland H. Stauber, Angelika Schnieke, Roland M. Schmid, Oliver H. Krämer, Dieter Saur & Günter Schneider. (2012) MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 11:8, pages 1593-1602.
Read now
Simon G. Royce & Tom C. Karagiannis. (2012) Histone Deacetylases and Their Role in Asthma. Journal of Asthma 49:2, pages 121-128.
Read now
Edwin F. de Zoeten, Liqing Wang, Kyle Butler, Ulf H. Beier, Tatiana Akimova, Hong Sai, James E. Bradner, Ralph Mazitschek, Alan P. Kozikowski, Patrick Matthias & Wayne W. Hancock. (2011) Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells. Molecular and Cellular Biology 31:10, pages 2066-2078.
Read now

Articles from other publishers (206)

Aparajita Ghosh, Ambati Himaja, Swati Biswas, Onkar Kulkarni & Balaram Ghosh. (2023) Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer. Molecular Pharmaceutics 20:12, pages 5981-6009.
Crossref
Juanbin Yin, Shasha Wang, Shanhui Ren, Zhengji Liang, Junwei Ge, Yuefeng Sun, Xiangping Yin & Xiangwei Wang. (2023) TMP269, a small molecule inhibitor of class IIa HDAC, suppresses RABV replication in vitro. Frontiers in Microbiology 14.
Crossref
Yawen Yang, Qingqing Liu, Xinyi Wang & Shaohua Gou. (2023) Design, Synthesis, and Biological Evaluation of Histone Deacetylase Inhibitors Derived from Erianin and Its Derivatives. ChemMedChem 18:13.
Crossref
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, Sangh Partap, Rajshekhar Karpoormath, Brajesh Kumar & Deepak Kumar. (2023) Recent advancement of HDAC inhibitors against breast cancer. Medical Oncology 40:7.
Crossref
Qing He, Changzhi Yu, Yang Li, Peng Hao, Hantao Mai, Ruilian Guo, Guifang Zhong, Kelin Zhang, Chipiu Wong, Qian Chen & Yantao Chen. (2021) ERRα contributes to HDAC6-induced chemoresistance of osteosarcoma cells. Cell Biology and Toxicology 39:3, pages 813-825.
Crossref
Kapil Kumar, Ranjana Das, Barsha Thapa, Bharti Rakhecha, Sapna Srivastava, Kumari Savita, Monazza Israr, Debabrata Chanda, Dibyendu Banerjee, Karuna Shanker, DU Bawankule, Benedetta Santini, Maria Luisa Di Paolo, Lisa Dalla Via, Daniele Passarella & Arvind Singh Negi. (2023) Dual targeted 2-Benzylideneindanone pendant hydroxamic acid group exhibits selective HDAC6 inhibition along with tubulin stabilization effect. Bioorganic & Medicinal Chemistry 86, pages 117300.
Crossref
Susanna Molinari, Carol Imbriano, Viviana Moresi, Alessandra Renzini, Silvia Belluti, Biliana Lozanoska-Ochser, Giuseppe Gigli & Alessia Cedola. (2023) Histone deacetylase functions and therapeutic implications for adult skeletal muscle metabolism. Frontiers in Molecular Biosciences 10.
Crossref
Federico Capone, Cristian Sotomayor-Flores, David Bode, Rongling Wang, Daniele Rodolico, Stefano Strocchi & Gabriele G Schiattarella. (2022) Cardiac metabolism in HFpEF: from fuel to signalling. Cardiovascular Research 118:18, pages 3556-3575.
Crossref
Timothy A McKinsey, Roger Foo, Chukwuemeka George Anene-Nzelu, Joshua G Travers, Ronald J Vagnozzi, Natalie Weber & Thomas Thum. (2022) Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovascular Research 118:18, pages 3482-3498.
Crossref
Yue Huang, Zhiwei Rong, Liuchao Zhang, Zhenyi Xu, Jianxin Ji, Jia He, Weisha Liu, Yan Hou & Kang Li. (2023) HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development. Frontiers in Oncology 13.
Crossref
Nikolaos Garmpis, Christos Damaskos, Dimitrios Dimitroulis, Gregory Kouraklis, Anna Garmpi, Panagiotis Sarantis, Evangelos Koustas, Alexandros Patsouras, Iason Psilopatis, Efstathios A. Antoniou, Michail V. Karamouzis, Konstantinos Kontzoglou & Afroditi Nonni. (2022) Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer. Journal of Personalized Medicine 12:10, pages 1672.
Crossref
Tianze Jiang, Laozhi Xie, Songlei Zhou, Yipu Liu, Yukun Huang, Ni Mei, Fenfen Ma, Jingru Gong, Xiaoling Gao & Jun Chen. (2022) Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment. Journal of Nanobiotechnology 20:1.
Crossref
Rahma K. Alseksek, Wafaa S. Ramadan, Ekram Saleh & Raafat El-Awady. (2022) The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. International Journal of Molecular Sciences 23:15, pages 8141.
Crossref
Amir Ajoolabady, Hamid Aslkhodapasandhokmabad, Yuan Zhou & Jun Ren. (2022) Epigenetic modification in alcohol‐related liver diseases. Medicinal Research Reviews 42:4, pages 1463-1491.
Crossref
Yang Xu, Yameng Wang, Lulu Wang, Wenxing Liang & Qianqian Yang. (2022) Sodium Valproate Is Effective Against Botrytis cinerea Infection of Tomato by Enhancing Histone H3 Acetylation-Directed Gene Transcription and Triggering Tomato Fruit Immune Response . Phytopathology® 112:6, pages 1264-1272.
Crossref
Se Jin Oh, Hyo-Jung Lee, Kwon-Ho Song, Suyeon Kim, Eunho Cho, Jaeyoon Lee, Marcus W. Bosenberg & Tae Woo Kim. (2022) Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle. Journal of Clinical Investigation 132:6.
Crossref
Yiyue Feng, Yingmei Lu, Junfang Li, Honghua Zhang, Zhao Li, Hanzhong Feng, Xuemei Deng, Dan Liu, Tao Shi, Weifan Jiang, Yongxing He, Jian Zhang & Zhen Wang. (2022) Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo. European Journal of Medicinal Chemistry 227, pages 113888.
Crossref
Ning Jin, Tiffany L. George, Gregory A. Otterson, Claire Verschraegen, Haitao Wen, David Carbone, James Herman, Erin M. Bertino & Kai He. (2021) Advances in epigenetic therapeutics with focus on solid tumors. Clinical Epigenetics 13:1.
Crossref
Xi Kuang, Shuang ChenJitong LaoYongmin ChenDandan JiaLinzhi TuLin MaXiaoping LiaoWenjie ZhaoQifu Li. (2021) HDAC9 in the Injury of Vascular Endothelial Cell Mediated by P38 MAPK Pathway. Journal of Interferon & Cytokine Research 41:12, pages 439-449.
Crossref
O. I. Kravchuk, A. V. Burakov, N. G. Gornostaev, K. V. Mikhailov, K. I. Adameyko, A. D. Finoshin, A. A. Georgiev, V. S. Mikhailov, Y. E. Yeryukova, G. A. Rubinovsky, D. V. Zayts, G. R. Gazizova, O. A. Gusev, E. I. Shagimardanova & Y. V. Lyupina. (2021) Histone Deacetylases in the Process of Halisarca dujardini Cell Reaggregation. Russian Journal of Developmental Biology 52:5, pages 319-333.
Crossref
Yong Wang, Fen Liu, Chen Fang, Liyao Xu, Lin Chen, Zeyao Xu, Jiaquan Chen, Wei Peng, Biqi Fu & Yong Li. (2021) Combination of rapamycin and SAHA enhanced radiosensitization by inducing autophagy and acetylation in NSCLC. Aging 13:14, pages 18223-18237.
Crossref
Kenny Man, Mathieu Y. Brunet, Maria Fernandez‐Rhodes, Soraya Williams, Liam M. Heaney, Lee A. Gethings, Angelica Federici, Owen G. Davies, David Hoey & Sophie C. Cox. (2021) Epigenetic reprogramming enhances the therapeutic efficacy of osteoblast‐derived extracellular vesicles to promote human bone marrow stem cell osteogenic differentiation. Journal of Extracellular Vesicles 10:9.
Crossref
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Vasiliki E. Georgakopoulou, Panagiotis Sarantis, Efstathios A. Antoniou, Michalis V. Karamouzis, Afroditi Nonni, Dimitrios Schizas, Evangelos Diamantis, Evangelos Koustas, Paraskevi Farmaki, Athanasios Syllaios, Alexandros Patsouras, Konstantinos Kontzoglou, Nikolaos Trakas & Dimitrios Dimitroulis. (2021) Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities. Journal of Personalized Medicine 11:3, pages 223.
Crossref
Aleksandra Kosianova, Vladlena Tiasto, Margarita Yatsunskaya, Yuri Khotimchenko & Alexander Kagansky. (2020) Natural molecules as modulators of epigenetic silencing in human cells for cancer care and aging. Biological Communications 65:4.
Crossref
Oleksiy Klymenko, Tim Brecklinghaus, Matthias Dille, Christian Springer, Christian de Wendt, Delsi Altenhofen, Christian Binsch, Birgit Knebel, Jürgen Scheller, Christopher Hardt, Ralf Herwig, Alexandra Chadt, Paul T. Pfluger, Hadi Al-Hasani & Dhiraj G. Kabra. (2020) Histone deacetylase 5 regulates interleukin 6 secretion and insulin action in skeletal muscle. Molecular Metabolism 42, pages 101062.
Crossref
Xiaopeng Peng, Zhiqiang Sun, Peihua Kuang & Jianjun Chen. (2020) Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. European Journal of Medicinal Chemistry 208, pages 112831.
Crossref
Xiaona Chen, Yanhong He, Wenjun Fu, Amirhossein Sahebkar, Yuhui Tan, Suowen Xu & Hong Li. (2020) Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review. Frontiers in Cell and Developmental Biology 8.
Crossref
Richard E. Phillips, Alexey A. Soshnev & C. David Allis. (2020) Epigenomic Reprogramming as a Driver of Malignant Glioma. Cancer Cell 38:5, pages 647-660.
Crossref
Monica Phimmachanh, Jeremy Z. R. Han, Yolande E. I. O’Donnell, Sharissa L. Latham & David R. Croucher. (2020) Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma. Frontiers in Cell and Developmental Biology 8.
Crossref
Wenli Fan, Lihui Zhang, Qixao Jiang, Weiguo Song, Fang Yan & Lei Zhang. (2020) Histone deacetylase inhibitor based prodrugs. European Journal of Medicinal Chemistry 203, pages 112628.
Crossref
Vivek Kumar Sharma, Vineet Mehta & Thakur Gurjeet Singh. (2020) Alzheimer’s Disorder: Epigenetic Connection and Associated Risk Factors. Current Neuropharmacology 18:8, pages 740-753.
Crossref
Annabelle Friedrich, Ann-Sophie Assmann, Lena Schumacher, Jana v. Stuijvenberg, Matthias U. Kassack, Wolfgang A. Schulz, Wynand P. Roos, Finn K. Hansen, Marc Pflieger, Thomas Kurz & Gerhard Fritz. (2020) In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi). International Journal of Molecular Sciences 21:13, pages 4747.
Crossref
Kanagaraj Subramanian, Darren M. Hutt, Samantha M. Scott, Vijay Gupta, Shu Mao & William E. Balch. (2020) Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid. Journal of Biological Chemistry 295:23, pages 8017-8035.
Crossref
Yuwen He, Danyang Chen, Yanmei Yi, Shanshan Zeng, Shuang Liu, Pan Li, Hui Xie, Pengjiu Yu, Guanmin Jiang & Hao Liu. (2020) Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149. Molecular Therapy - Oncolytics 17, pages 448-459.
Crossref
Surabhi Shukla & Babu L. Tekwani. (2020) Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Frontiers in Pharmacology 11.
Crossref
Sachan Richa, Prasanta Dey, Chaeun Park, Jungho Yang, Ji Yeon Son, Jae Hyeon Park, Su Hyun Lee, Mee-Young Ahn, In Su Kim, Hyung Ryong Moon & Hyung Sik Kim. (2020) A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells. Biomolecules & Therapeutics 28:2, pages 184-194.
Crossref
Kentaro Igarashi, Kei Kawaguchi, Ming Zhao, Tasuku Kiyuna, Kentaro Miyake, Masuyo Miyake, Scott D. Nelson, Sarah M. Dry, Yunfeng Li, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Takashi Higuchi, Shree Ram Singh, Hiroyuki Tsuchiya & Robert M. Hoffman. (2020) Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. Translational Oncology 13:2, pages 393-400.
Crossref
P. Ann Boriack‐Sjodin. 2020. Structural Biology in Drug Discovery. Structural Biology in Drug Discovery 423 448 .
Ka Yi Tsui, Robert J. Tombari, David E. Olson & Dean J. Tantillo. (2019) Reconsidering the Structure of Serlyticin-A. Journal of Natural Products 82:12, pages 3464-3468.
Crossref
Linyu Yang, Qiang Qiu, Minghai Tang, Fang Wang, Yuyao Yi, Dongni Yi, Zhuang Yang, Zejiang Zhu, Shoujun Zheng, Jianhong Yang, Heying Pei, Li Zheng, Yong Chen, Liping Gou, Liya Luo, Xing Deng, Haoyu Ye, Yiguo Hu, Ting Niu & Lijuan Chen. (2019) Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL –Induced B-Cell Acute Lymphoblastic Leukemia . Clinical Cancer Research 25:24, pages 7527-7539.
Crossref
Xiaodi Qiu, Xianfang Rong, Jin Yang & Yi Lu. (2019) Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure. BMC Ophthalmology 19:1.
Crossref
Yanhua Zhang, Hui Xie, Wenyan Tang, Xingda Zeng, Yu Lin, Lian Xu, Lihua Xiao, Jun Xu, Zhongdao Wu & Dongjuan Yuan. (2019) Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus cantonensis Infection in Mice. Frontiers in Microbiology 10.
Crossref
Mamdouh F.A. Mohamed, Bahaa G.M. Youssif, Montaser Sh. A. Shaykoon, Mostafa H. Abdelrahman, Bakheet E.M. Elsadek, Ahmed S. Aboraia & Gamal El-Din A. Abuo-Rahma. (2019) Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors. Bioorganic Chemistry 91, pages 103127.
Crossref
Joanna Jaworska, Teresa Zalewska, Joanna Sypecka & Malgorzata Ziemka-Nalecz. (2019) Effect of the HDAC Inhibitor, Sodium Butyrate, on Neurogenesis in a Rat Model of Neonatal Hypoxia–Ischemia: Potential Mechanism of Action. Molecular Neurobiology 56:9, pages 6341-6370.
Crossref
Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, Zhangguo Chen, Gan Zhang, Anthony D. Piscopio, Xuedong Liu & Jing H. Wang. (2019) Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas. Cancer Immunology Research 7:8, pages 1318-1331.
Crossref
Yong Ling, Yangyang Li, Rui Zhu, Jianqiang Qian, Ji Liu, Weijie Gao, Chi Meng, Jiefei Miao, Biao Xiong, Xiaodong Qiu, Changchun Ling, Hong Dai & Yanan Zhang. (2019) Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways. Journal of Natural Products 82:6, pages 1442-1450.
Crossref
Victoria A. Jennings, Gina B. Scott, Ailsa M.S. Rose, Karen J. Scott, Gemma Migneco, Brian Keller, Katrina Reilly, Oliver Donnelly, Howard Peach, Donald Dewar, Kevin J. Harrington, Hardev Pandha, Adel Samson, Richard G. Vile, Alan A. Melcher & Fiona Errington-Mais. (2019) Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy 27:6, pages 1139-1152.
Crossref
Antonino Cattaneo & Michele Chirichella. (2019) Targeting the Post-translational Proteome with Intrabodies. Trends in Biotechnology 37:6, pages 578-591.
Crossref
Kajal Thapa, Savir Kumar, Anurag Sharma, Sandeep Arora, Amarjot Kaur Grewal & Thakur Gurjeet Singh. (2019) Histone Deacetylase Inhibitors As Potential Therapeutic Agents For Various Disorders. Journal of Pharmaceutical Technology, Research and Management 5:2, pages 235-253.
Crossref
Min Yang, Gen Chen, Xue Zhang, Yuliang Guo, Yan Yu, Li Tian, Sheng Chang & Zhonghua Klaus Chen. (2019) Inhibition of class I HDACs attenuates renal interstitial fibrosis in a murine model. Pharmacological Research 142, pages 192-204.
Crossref
Qiuhang Song, Mingyue Li, Cong Fan, Yucui Liu, Lihua Zheng, Yongli Bao, Luguo Sun, Chunlei Yu, Zhenbo Song, Ying Sun, Guannan Wang, Yanxin Huang & Yuxin Li. (2019) A novel benzamine lead compound of histone deacetylase inhibitor ZINC24469384 can suppresses HepG2 cells proliferation by upregulating NR1H4. Scientific Reports 9:1.
Crossref
Yoojin Song, Jiah Lim & Young Ho Seo. (2019) A novel class of anthraquinone-based HDAC6 inhibitors. European Journal of Medicinal Chemistry 164, pages 263-272.
Crossref
Allyson Flower & Oussama Abla. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas 87 110 .
Marina B. Felisbino & Timothy A. McKinsey. (2018) Epigenetics in Cardiac Fibrosis. JACC: Basic to Translational Science 3:5, pages 704-715.
Crossref
Nilanjan Adhikari, Sk. Abdul Amin, Prakruti Trivedi, Tarun Jha & Balaram Ghosh. (2018) HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches. European Journal of Medicinal Chemistry 157, pages 1127-1142.
Crossref
Varsha J. Thombare & Craig A. Hutton. (2018) Bridged bicyclic peptides: Structure and function. Peptide Science 110:3.
Crossref
Alanna Sedgwick, M. Olivia Balmert & Crislyn D’Souza-Schorey. (2018) The formation of giant plasma membrane vesicles enable new insights into the regulation of cholesterol efflux. Experimental Cell Research 365:2, pages 194-207.
Crossref
Pavel Štarha, Zdeněk Trávníček, Bohuslav Drahoš, Radovan Herchel & Zdeněk Dvořák. (2018) Cell-based studies of the first-in-class half-sandwich Ir(III) complex containing histone deacetylase inhibitor 4-phenylbutyrate. Applied Organometallic Chemistry 32:4, pages e4246.
Crossref
Sarah J. Mitchell, Michel Bernier, Miguel A. Aon, Sonia Cortassa, Eun Young Kim, Evandro F. Fang, Hector H. Palacios, Ahmed Ali, Ignacio Navas-Enamorado, Andrea Di Francesco, Tamzin A. Kaiser, Tyler B. Waltz, Ning Zhang, James L. Ellis, Peter J. Elliott, David W. Frederick, Vilhelm A. Bohr, Mark S. Schmidt, Charles Brenner, David A. Sinclair, Anthony A. Sauve, Joseph A. Baur & Rafael de Cabo. (2018) Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice. Cell Metabolism 27:3, pages 667-676.e4.
Crossref
Talal Jamil Qazi, Zhenzhen Quan, Asif Mir & Hong Qing. (2017) Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation. Molecular Neurobiology 55:2, pages 1026-1044.
Crossref
Pavel Štarha, Zdeněk Trávníček, Radovan Herchel, Pawel Jewula & Zdeněk Dvořák. (2018) A potential method to improve the in vitro cytotoxicity of half-sandwich Os( ii ) complexes against A2780 cells . Dalton Transactions 47:16, pages 5714-5724.
Crossref
Xiaoru Sun, Zhihong Chen & Xiangdong Wang. 2018. Genomic Approach to Asthma. Genomic Approach to Asthma 243 275 .
Tino Heimburg, Fiona R. Kolbinger, Patrik Zeyen, Ehab Ghazy, Daniel Herp, Karin Schmidtkunz, Jelena Melesina, Tajith Baba Shaik, Frank Erdmann, Matthias Schmidt, Christophe Romier, Dina Robaa, Olaf Witt, Ina Oehme, Manfred Jung & Wolfgang Sippl. (2017) Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity. Journal of Medicinal Chemistry 60:24, pages 10188-10204.
Crossref
Sridhar Murahari, Aimee L. Jalkanen, Samuel K. Kulp, Ching-Shih Chen, Jaime F. Modiano, Cheryl A. London & William C. Kisseberth. (2017) Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer 17:1.
Crossref
Arathi Jayaraman, Advait Soni, Bellur S. Prabhakar, Mark Holterman & Sundararajan Jayaraman. (2017) The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord. Neurobiology of Disease 108, pages 1-12.
Crossref
Fabiana Pandolfi, Isabella Chiarotto, Daniele Rocco & Marta Feroci. (2017) Electrogenerated superoxide anion induced oxidative amidation of benzoin. Electrochimica Acta 254, pages 358-367.
Crossref
Ying-Chao Duan, Yong-Cheng Ma, Wen-Ping Qin, Li-Na Ding, Yi-Chao Zheng, Ying-Li Zhu, Xiao-Yu Zhai, Jing Yang, Chao-Ya Ma & Yuan-Yuan Guan. (2017) Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment. European Journal of Medicinal Chemistry 140, pages 392-402.
Crossref
Stefani N. Thomas, Lijun Chen, Yang Liu, Naseruddin Höti & Hui Zhang. (2017) Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas. Journal of Proteome Research 16:10, pages 3704-3710.
Crossref
Weston W Blakeslee, Kimberly M Demos-Davies, Douglas D Lemon, Katharina M Lutter, Maria A Cavasin, Sam Payne, Karin Nunley, Carlin S Long, Timothy A McKinsey & Shelley D Miyamoto. (2017) Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy. Pediatric Research 82:4, pages 642-649.
Crossref
Eva Bernhart, Nicole Stuendl, Heike Kaltenegger, Christian Windpassinger, Nicholas Donohue, Andreas Leithner & Birgit Lohberger. (2017) Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines. Oncotarget 8:44, pages 77254-77267.
Crossref
Kwon-Ho Song, Chel Hun Choi, Hyo-Jung Lee, Se Jin Oh, Seon Rang Woo, Soon-Oh Hong, Kyung Hee Noh, Hanbyoul Cho, Eun Joo Chung, Jae-Hoon Kim, Joon-Yong Chung, Stephen M. Hewitt, Seungki Baek, Kyung-Mi Lee, Cassian Yee, Minjoo Son, Chih-Ping Mao, T.C. Wu & Tae Woo Kim. (2017) HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells. Cancer Research 77:18, pages 5039-5053.
Crossref
Shivangi Agarwal & Dileep Varma. (2017) Targeting mitotic pathways for endocrine-related cancer therapeutics. Endocrine-Related Cancer 24:9, pages T65-T82.
Crossref
Thea van den Bosch, Marcel Kwiatkowski, Rainer Bischoff & Frank J Dekker. (2017) Targeting transcription factor lysine acetylation in inflammatory airway diseases. Epigenomics 9:7, pages 1013-1028.
Crossref
Zhibing Wu, Saisai Jing, Yanhong Li, Yabo Gao, Shuhuan Yu, Zhitian Li, Yanyan Zhao, Jigang Piao, Shenglin Ma & Xufeng Chen. (2017) The effects of SAHA on radiosensitivity in pancreatic cancer cells by inducing apoptosis and targeting RAD51. Biomedicine & Pharmacotherapy 89, pages 705-710.
Crossref
Hui Zhang, Yu-Ping Shang, Hong-ying Chen & Jun Li. (2017) Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatology Research 47:2, pages 149-159.
Crossref
Akira Kurozumi, Yusuke Goto, Atsushi Okato & Naohiko Seki. 2017. DNA and Histone Methylation as Cancer Targets. DNA and Histone Methylation as Cancer Targets 281 296 .
Martin Wieczorek, Karl-Heinz Gührs & Thorsten Heinzel. 2017. HDAC/HAT Function Assessment and Inhibitor Development. HDAC/HAT Function Assessment and Inhibitor Development 313 327 .
Hui-Wen Chiu, Ya-Ling Yeh, Yi-Ching Wang, Wei-Jan Huang, Sheng-Yow Ho, Pinpin Lin & Ying-Jan Wang. (2016) Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. Molecular Cancer 15:1.
Crossref
Yu Tina Zhao, Hao Wang, Shouyan Zhang, Jianfeng Du, Shougang Zhuang & Ting C. Zhao. (2016) Irisin Ameliorates Hypoxia/Reoxygenation-Induced Injury through Modulation of Histone Deacetylase 4. PLOS ONE 11:11, pages e0166182.
Crossref
Toros A. Dincman, Jason E. Beare, Sujata Saraswat Ohri, Vittorio Gallo, Michal Hetman & Scott R. Whittemore. (2016) Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo . International Journal of Developmental Neuroscience 54:1, pages 53-61.
Crossref
Haya Jamali, Hasan A. Khan, Caroline C. Tjin & Jonathan A. Ellman. (2016) Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors. ACS Medicinal Chemistry Letters 7:9, pages 847-851.
Crossref
Katherine B Schuetze, Keith A Koch & Timothy A McKinsey. (2016) The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases. Future Medicinal Chemistry 8:13, pages 1533-1536.
Crossref
Boopathi Subramaniyan, Kaviya Jagadeesan, Sabitha Ramakrishnan & Ganeshan Mathan. (2016) Targeting the interaction of Aurora kinases and SIRT1 mediated by Wnt signaling pathway in colorectal cancer: A critical review. Biomedicine & Pharmacotherapy 82, pages 413-424.
Crossref
Mohammed Manal, M.J.N. Chandrasekar, Jeyapal Gomathi Priya & M.J. Nanjan. (2016) Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorganic Chemistry 67, pages 18-42.
Crossref
Paul G Richardson. (2016) Dual inhibition of oncogenic targets for B-cell malignancies. The Lancet Oncology 17:5, pages 547-549.
Crossref
Anas Younes, Jesus G Berdeja, Manish R Patel, Ian Flinn, John F Gerecitano, Sattva S Neelapu, Kevin R Kelly, Amanda R Copeland, Amy Akins, Myles S Clancy, Lucy Gong, Jing Wang, Anna Ma, Jaye L Viner & Yasuhiro Oki. (2016) Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. The Lancet Oncology 17:5, pages 622-631.
Crossref
Deli Zhang, Xu Hu, Robert H. Henning & Bianca J.J.M. Brundel. (2016) Keeping up the balance: role of HDACs in cardiac proteostasis and therapeutic implications for atrial fibrillation. Cardiovascular Research 109:4, pages 519-526.
Crossref
Anna Leonidova, Cristina Mari, Christine Aebersold & Gilles Gasser. (2016) Selective Photorelease of an Organometallic-Containing Enzyme Inhibitor. Organometallics 35:6, pages 851-854.
Crossref
Rayne R. Lim, Alison Tan, Yu-Chi Liu, Veluchamy A. Barathi, Rajiv R. Mohan, Jodhbir S. Mehta & Shyam S. Chaurasia. (2016) ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis. Scientific Reports 6:1.
Crossref
Boonsil Jang, Ji-Ae Shin, Yong-Soo Kim, Ji-Young Kim, Ho-Keun Yi, Il-Song Park, Nam-Pyo Cho & Sung-Dae Cho. (2015) Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells. Cellular Oncology 39:1, pages 79-87.
Crossref
S Baig, I Seevasant, J Mohamad, A Mukheem, H Z Huri & T Kamarul. (2016) Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?. Cell Death & Disease 7:1, pages e2058-e2058.
Crossref
Heidi Olzscha, Mina E. Bekheet, Semira Sheikh & Nicholas B. La Thangue. 2016. Histone Deacetylases. Histone Deacetylases 281 303 .
Kimberly P. Keil, Helene M. Altmann, Lisa L. Abler, Laura L. Hernandez & Chad M. Vezina. (2015) Histone acetylation regulates prostate ductal morphogenesis through a bone morphogenetic protein-dependent mechanism. Developmental Dynamics 244:11, pages 1404-1414.
Crossref
M. FRANEK, S. LEGARTOVÁ, J. SUCHÁNKOVÁ, C. MILITE, S. CASTELLANO, G. SBARDELLA, S. KOZUBEK & E. BÁRTOVÁ. (2015) CARM1 Modulators Affect Epigenome of Stem Cells and Change Morphology of Nucleoli. Physiological Research, pages 769-782.
Crossref
Hiroshi Nakashima, Johanna K. Kaufmann, Pin-Yi Wang, Tran Nguyen, Maria-Carmela Speranza, Kazue Kasai, Kazuo Okemoto, Akihiro Otsuki, Ichiro Nakano, Soledad Fernandez, William F. Goins, Paola Grandi, Joseph C. Glorioso, Sean Lawler, Timothy P. Cripe & E. Antonio Chiocca. (2015) Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. Journal of Clinical Investigation 125:11, pages 4269-4280.
Crossref
Yang Cai, Xiang Yan, Guoqing Zhang, Weihong Zhao & Shunchang Jiao. (2015) The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Oncotarget 6:22, pages 18997-19005.
Crossref
Roy Lardenoije, Artemis Iatrou, Gunter Kenis, Konstantinos Kompotis, Harry W.M. Steinbusch, Diego Mastroeni, Paul Coleman, Cynthia A. Lemere, Patrick R. Hof, Daniel L.A. van den Hove & Bart P.F. Rutten. (2015) The epigenetics of aging and neurodegeneration. Progress in Neurobiology 131, pages 21-64.
Crossref
Apei Jiang, Xuemin Wang, Xiaoyun Shan, Yuan Li, Pengqi Wang, Pan Jiang & Qing Feng. (2015) Curcumin Reactivates Silenced Tumor Suppressor Gene RARβ by Reducing DNA Methylation. Phytotherapy Research 29:8, pages 1237-1245.
Crossref
Ferdinando ChiaradonnaClaudia CirulliRoberta PaloriniGiuseppina VottaLilia Alberghina. (2015) New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer. Antioxidants & Redox Signaling 23:1, pages 30-50.
Crossref
Santhosh K. ManiChristine B. KernDenise KimbroughBenjamin AddyHarinath KasiganesanWilliam T. RiversRisha K. PatelJames C. ChouFrancis G. Spinale, Rupak MukherjeeDonald R. Menick. (2015) Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 308:11, pages H1391-H1401.
Crossref
Mao Cai, Jie Hu, Ji-Lai Tian, Huang Yan, Chen-Guo Zheng & Wan-Le Hu. (2015) Novel hybrids from N-hydroxyarylamide and indole ring through click chemistry as histone deacetylase inhibitors with potent antitumor activities. Chinese Chemical Letters 26:6, pages 675-680.
Crossref
Xia-xia Zheng, Tian Zhou, Xin-An Wang, Xiao-hong Tong & Jia-wang Ding. (2015) Histone deacetylases and atherosclerosis. Atherosclerosis 240:2, pages 355-366.
Crossref
Jianfeng Du, Ling Zhang, Shougang Zhuang, Gang Jian Qin & Ting cun Zhao. (2015) HDAC4 Degradation Mediates HDAC Inhibition-Induced Protective Effects Against Hypoxia/Reoxygenation Injury. Journal of Cellular Physiology 230:6, pages 1321-1331.
Crossref
Jih-Tung Pai, Chia-Yun Hsu, Kuo-Tai Hua, Sheng-Yung Yu, Chung-Yang Huang, Chia-Nan Chen, Chiung-Ho Liao & Meng-Shih Weng. (2015) NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells. Molecules 20:5, pages 8000-8019.
Crossref
Christian Schölz, Brian T Weinert, Sebastian A Wagner, Petra Beli, Yasuyuki Miyake, Jun Qi, Lars J Jensen, Werner Streicher, Anna R McCarthy, Nicholas J Westwood, Sonia Lain, Jürgen Cox, Patrick Matthias, Matthias Mann, James E Bradner & Chunaram Choudhary. (2015) Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nature Biotechnology 33:4, pages 415-423.
Crossref
Matthew D. Christensen, Jacob J. Elmer, Seron Eaton, Laura Gonzalez-Malerva, Joshua LaBaer & Kaushal Rege. (2015) Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. Journal of Controlled Release 204, pages 20-29.
Crossref
Kazumasa Aoyama, Noritaka Yamaguchi, Ryuzaburo Yuki, Mariko Morii, Sho Kubota, Kensuke Hirata, Kohei Abe, Takuya Honda, Takahisa Kuga, Yuuki Hashimoto, Takeshi Tomonaga & Naoto Yamaguchi. (2015) c-Abl induces stabilization of histone deacetylase 1 (HDAC1) in a kinase activity-dependent manner. Cell Biology International 39:4, pages 446-456.
Crossref
Loredana Vesci, Elena Bernasconi, Ferdinando Maria Milazzo, Rita De Santis, Eugenio Gaudio, Ivo Kwee, Andrea Rinaldi, Silvia Pace, Valeria Carollo, Giuseppe Giannini & Francesco Bertoni. (2014) Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget 6:8, pages 5735-5748.
Crossref
Haya Jamali, Hasan A. Khan, Joseph R. Stringer, Somenath Chowdhury & Jonathan A. Ellman. (2015) Identification of Multiple Structurally Distinct, Nonpeptidic Small Molecule Inhibitors of Protein Arginine Deiminase 3 Using a Substrate-Based Fragment Method. Journal of the American Chemical Society 137:10, pages 3616-3621.
Crossref
Anil Rana, Jimi Marin Alex, Monika Chauhan, Gaurav Joshi & Raj Kumar. (2014) A review on pharmacophoric designs of antiproliferative agents. Medicinal Chemistry Research 24:3, pages 903-920.
Crossref
Yunfei Wang, Ryan L. Stowe, Christie E. Pinello, Guimei Tian, Franck Madoux, Dawei Li, Lisa Y. Zhao, Jian-Liang Li, Yuren Wang, Yuan Wang, Haiching Ma, Peter Hodder, William R. Roush & Daiqing Liao. (2015) Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases. Chemistry & Biology 22:2, pages 273-284.
Crossref
Hai-Ying Li, Hai-Ge Ye, Chi-Qi Chen, Li-Hui Yin, Jian-Bo Wu, Li-Cai He & Shen-Meng Gao. (2015) Honokiol Induces Cell Cycle Arrest and Apoptosis Via Inhibiting Class I Histone Deacetylases in Acute Myeloid Leukemia. Journal of Cellular Biochemistry 116:2, pages 287-298.
Crossref
Frank P. Vendetti, Michael Topper, Peng Huang, Irina Dobromilskaya, Hariharan Easwaran, John Wrangle, Stephen B. Baylin, J. T. Poirier & Charles M. Rudin. (2014) Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 6:1, pages 56-70.
Crossref
Hua Zhang, Xufeng Dai, Yan Qi, Ying He, Wei Du & Ji-jing Pang. (2015) Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives. Journal of Ophthalmology 2015, pages 1-9.
Crossref
Santosh S. Hanmod, Guan Wang, Holly Edwards, Steven A. Buck, Yubin Ge, Jeffrey W. Taub & Zhihong Wang. (2015) Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma. Pediatric Blood & Cancer 62:1, pages 52-59.
Crossref
Philipp Anstaett & Gilles Gasser. 2014. Bioorganometallic Chemistry. Bioorganometallic Chemistry 1 42 .
Riccardo Petrelli, Maria Meli, Patrizia Vita, Ilaria Torquati, Arianna Ferro, Munender Vodnala, Natale D’Alessandro, Manlio Tolomeo, Fabio Del Bello, Praveen Kusumanchi, Palmarisa Franchetti, Mario Grifantini, Hiremagalur N. Jayaram, Anders Hofer & Loredana Cappellacci. (2014) From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: Synthesis and biological evaluation of valproic esters of 3′-C-methyladenosine. Bioorganic & Medicinal Chemistry Letters 24:22, pages 5304-5309.
Crossref
Ramón Cacabelos. (2014) Epigenomic Networking in Drug Development: From Pathogenic Mechanisms to Pharmacogenomics. Drug Development Research 75:6, pages 348-365.
Crossref
Brook T. ChernetMichael Levin. (2014) Transmembrane voltage potential of somatic cells controls oncogene-mediated tumorigenesis at long-range. Oncotarget 5:10, pages 3287-3306.
Crossref
Katherine B. Schuetze, Timothy A. McKinsey & Carlin S. Long. (2014) Targeting cardiac fibroblasts to treat fibrosis of the heart: Focus on HDACs. Journal of Molecular and Cellular Cardiology 70, pages 100-107.
Crossref
Stefan H E Kaufmann, Christoph Lange, Martin Rao, Kithiganahalli N Balaji, Michael Lotze, Marco Schito, Alimuddin I Zumla & Markus Maeurer. (2014) Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review. The Lancet Respiratory Medicine 2:4, pages 301-320.
Crossref
Chih-Chien Chou, Santosh B. Salunke, Samuel K. Kulp & Ching-Shih Chen. (2014) Prospects on Strategies for Therapeutically Targeting Oncogenic Regulatory Factors by Small-Molecule Agents. Journal of Cellular Biochemistry 115:4, pages 611-624.
Crossref
Y Zhu, K Das, J Wu, M H Lee & P Tan. (2013) RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells. Oncogene 33:12, pages 1527-1537.
Crossref
Simon G. Royce, Yuben Moodley & Chrishan S. Samuel. (2014) Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis. Pharmacology & Therapeutics 141:3, pages 250-260.
Crossref
Tao You, Ke Chen, Fei-Hai Wang, Pi-Hong Li, Li-Yi Li, Zhi-Hao Wu, Kong-Hai Ni & Zhi-Qiang Zheng. (2014) Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors. Chinese Chemical Letters 25:3, pages 474-478.
Crossref
MICHEL PINHEIRO DOS SANTOS, CAROLINE BRUNETTO DE FARIAS, RAFAEL ROESLER, ALGEMIR LUNARDI BRUNETTO & ANA LUCIA ABUJAMRA. (2014) In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: A paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncology Reports 31:2, pages 955-968.
Crossref
Simon G. Royce & Tom C. Karagiannis. (2014) Histone deacetylases and their inhibitors. Current Opinion in Allergy & Clinical Immunology 14:1, pages 44-48.
Crossref
Sarah M. Williams, Lucy Golden-Mason, Bradley S. Ferguson, Katherine B. Schuetze, Maria A. Cavasin, Kim Demos-Davies, Michael E. Yeager, Kurt R. Stenmark & Timothy A. McKinsey. (2014) Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. Journal of Molecular and Cellular Cardiology 67, pages 112-125.
Crossref
Juliann Chmielecki & Matthew Meyerson. (2014) DNA Sequencing of Cancer: What Have We Learned?. Annual Review of Medicine 65:1, pages 63-79.
Crossref
Shiliang Tu, Hang Yuan, Jie Hu, Chengguang Zhao, Rui Chai & Hongfeng Cao. (2014) Design, Synthesis and Biological Evaluation of Nitro Oxide Donating <i>N</i>-Hydroxycinnamamide Derivatives as Histone Deacetylase Inhibitors. Chemical and Pharmaceutical Bulletin 62:12, pages 1185-1191.
Crossref
Shinji Kuroda, Shunsuke Kagawa & Toshiyoshi Fujiwara. 2014. Gene Therapy of Cancer. Gene Therapy of Cancer 171 183 .
David M. Woods, Maritza Lienlaf-Moreno, Eduardo Sotomayor, Edward Seto & Alejandro Villagra. 2014. Nuclear Signaling Pathways and Targeting Transcription in Cancer. Nuclear Signaling Pathways and Targeting Transcription in Cancer 155 187 .
Ying Cai, Wenli Cui, Weixiang Chen, Ping Wei, Yayun Chi, Ping Zhang, Rui Bi & Xiaoyan Zhou. (2013) The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms. Cancer Cell International 13:1.
Crossref
Chengzhi Xie, Christina Drenberg, Holly Edwards, J. Timothy Caldwell, Wei Chen, Hiroto Inaba, Xuelian Xu, Steven A. Buck, Jeffrey W. Taub, Sharyn D. Baker & Yubin Ge. (2013) Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. PLoS ONE 8:11, pages e79106.
Crossref
Shu-Fu Lin, Jen-Der Lin, Ting-Chao Chou, Yu-Yao Huang & Richard J. Wong. (2013) Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. PLoS ONE 8:10, pages e77684.
Crossref
David M. Woods, Karrune Woan, Fengdong Cheng, Hongwei Wang, Patricio Perez-Villarroel, Calvin Lee, Maritza Lienlaf, Peter Atadja, Edward Seto, Jeffrey Weber, Eduardo M. Sotomayor & Alejandro Villagra. (2013) The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Research 23:5, pages 341-348.
Crossref
Banzhou PanJun YiHaizhu Song. (2013) MicroRNA-Mediated Autophagic Signaling Networks and Cancer Chemoresistance. Cancer Biotherapy and Radiopharmaceuticals 28:8, pages 573-578.
Crossref
Guan Wang, Holly Edwards, J. Timothy Caldwell, Steven A. Buck, William Y. Qing, Jeffrey W. Taub, Yubin Ge & Zhihong Wang. (2013) Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells. PLoS ONE 8:9, pages e76662.
Crossref
Jun Wang, Jin-Tai Yu, Meng-Shan Tan, Teng Jiang & Lan Tan. (2013) Epigenetic mechanisms in Alzheimer's disease: Implications for pathogenesis and therapy. Ageing Research Reviews 12:4, pages 1024-1041.
Crossref
Soňa Legartová, Lenka Stixová, Hynek Strnad, Stanislav Kozubek, Nadine Martinet, Frank J Dekker, Michal Franek & Eva Bártová. (2013) Basic nuclear processes affected by histone acetyltransferases and histone deacetylase inhibitors. Epigenomics 5:4, pages 379-396.
Crossref
Luca A. Petruccelli, Filippa Pettersson, Sonia V. del Rincón, Cynthia Guilbert, Jonathan D. Licht & Wilson H. MillerJrJr. (2013) Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis. Molecular Cancer Therapeutics 12:8, pages 1591-1604.
Crossref
Joel M. Gottesfeld, James R. Rusche & Massimo Pandolfo. (2013) Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. Journal of Neurochemistry 126, pages 147-154.
Crossref
Melanie R. Shakespear, Daniel M. Hohenhaus, Greg M. Kelly, Nabilah A. Kamal, Praveer Gupta, Larisa I. Labzin, Kate Schroder, Valerie Garceau, Sheila Barbero, Abishek Iyer, David A. Hume, Robert C. Reid, Katharine M. Irvine, David P. Fairlie & Matthew J. Sweet. (2013) Histone Deacetylase 7 Promotes Toll-like Receptor 4-dependent Proinflammatory Gene Expression in Macrophages. Journal of Biological Chemistry 288:35, pages 25362-25374.
Crossref
Hsueh-Yun Lee, Chia-Ron Yang, Mei-Jung Lai, Han-Li Huang, Yi-Ling Hsieh, Yi-Min Liu, Teng-Kuang Yeh, Yu-Hsuan Li, Samir Mehndiratta, Che-Ming Teng & Jing-Ping Liou. (2013) 1-Arylsulfonyl-5-( N -hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors . ChemBioChem 14:10, pages 1248-1254.
Crossref
EUN-SUN CHOI, GYOONHEE HAN, SONG-KYU PARK, KIHO LEE, HYUN-JUNG KIM, SUNG-DAE CHO & HWAN MOOK KIM. (2013) A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells. Molecular Medicine Reports 8:1, pages 195-200.
Crossref
Chi-qi Chen, Kang Yu, Qing-xian Yan, Chong-yun Xing, Yi Chen, Zhuang Yan, Yi-fen Shi, Ke-Wen Zhao & Shen-meng Gao. (2013) Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class Ι histone deacetylases. Carcinogenesis 34:7, pages 1442-1449.
Crossref
M-C Yen, T-Y Weng, Y-L Chen, C-C Lin, C-Y Chen, C-Y Wang, H-L Chao, C-S Chen & M-D Lai. (2013) An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA. Cancer Gene Therapy 20:6, pages 351-357.
Crossref
Jahangir Amin, Antonino Puglisi, James Clarke, John Milton, Minghua Wang, Ronald M. Paranal, James E. Bradner & John Spencer. (2013) A cyclodextrin-capped histone deacetylase inhibitor. Bioorganic & Medicinal Chemistry Letters 23:11, pages 3346-3348.
Crossref
Pamela D. Martin & David J. Argyle. 2013. Advances in Veterinary Dermatology. Advances in Veterinary Dermatology 187 196 .
Duo Lu. (2013) Epigenetic modification enzymes: catalytic mechanisms and inhibitors. Acta Pharmaceutica Sinica B 3:3, pages 141-149.
Crossref
N Nohata, T Hanazawa, T Kinoshita, A Inamine, N Kikkawa, T Itesako, H Yoshino, H Enokida, M Nakagawa, Y Okamoto & N Seki. (2013) Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. British Journal of Cancer 108:8, pages 1648-1658.
Crossref
Shen-meng Gao, Chi-qi Chen, Lu-yao Wang, Li-li Hong, Jian-bo Wu, Pei-hong Dong & Fu-jun Yu. (2013) Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Experimental Hematology 41:3, pages 261-270.e4.
Crossref
Pamela D. Martin & David J. Argyle. (2013) Advances in the management of skin cancer. Veterinary Dermatology 24:1, pages 173-e38.
Crossref
Koichi Narita, Yurie Fukui, Yui Sano, Takao Yamori, Akihiro Ito, Minoru Yoshida & Tadashi Katoh. (2013) Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities. European Journal of Medicinal Chemistry 60, pages 295-304.
Crossref
David M. Wilson, Lisa N. Silverman, Markus Bergauer & Kayvan R. Keshari. (2013) Solid phase synthesis of hydroxamate peptides for histone deacetylase inhibition. Tetrahedron Letters 54:2, pages 151-153.
Crossref
Chengzhi Xie, Holly Edwards, Salvatore B. LoGrasso, Steven A. Buck, Larry H. Matherly, Jeffrey W. Taub & Yubin Ge. (2012) Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood & Cancer 59:7, pages 1245-1251.
Crossref
Guan Wang, Jing He, Jianyun Zhao, Wenting Yun, Chengzhi Xie, Jeffrey W. Taub, Asfar Azmi, Ramzi M. Mohammad, Yan Dong, Wei Kong, Yingjie Guo & Yubin Ge. (2012) Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. PLoS ONE 7:12, pages e52095.
Crossref
Maria New, Heidi Olzscha & Nicholas B. La Thangue. (2012) HDAC inhibitor-based therapies: Can we interpret the code?. Molecular Oncology 6:6, pages 637-656.
Crossref
Jason H. Williams, Bhuvaneswari Jayaraman, Kathryn J. Swoboda & Jeffrey S. Barrett. (2013) Population Pharmacokinetics of Valproic Acid in Pediatric Patients With Epilepsy: Considerations for Dosing Spinal Muscular Atrophy Patients. The Journal of Clinical Pharmacology 52:11, pages 1676-1688.
Crossref
Marion Bouchecareilh, Darren M. Hutt, Patricia Szajner, Terence R. Flotte & William E. Balch. (2012) Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of α1-Antitrypsin Deficiency. Journal of Biological Chemistry 287:45, pages 38265-38278.
Crossref
Aniruddha J. Deshpande, James Bradner & Scott A. Armstrong. (2012) Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends in Immunology 33:11, pages 563-570.
Crossref
Maria Fadri‐Moskwik, Kimberly N. Weiderhold, Arpaporn Deeraksa, Carol Chuang, Jing Pan, Sue‐Hwa Lin & Li‐Yuan Yu‐Lee. (2012) Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. The FASEB Journal 26:10, pages 4057-4067.
Crossref
Jack-Michel Renoir. (2012) Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches. Steroids 77:12, pages 1249-1261.
Crossref
Kuen-Tyng Lin, Yi-Wei Wang, Chiung-Tong Chen, Chun-Ming Ho, Wen-Hui Su & Yuh-Shan Jou. (2012) HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy. Clinical Cancer Research 18:17, pages 4691-4701.
Crossref
Gerard Drewes. (2012) Future strategies in epigenetic drug discovery. Drug Discovery Today: Therapeutic Strategies 9:2-3, pages e121-e127.
Crossref
Schahram Akbarian. 2012. Epigenomics. Epigenomics 420 433 .
Michael P Holloway & Rachel A Altura. (2012) Targeting survivin’s co-conspirators: do alternative methods of trapping survivin in the nucleus have potential in triple-negative breast cancer therapy?. Future Oncology 8:8, pages 907-909.
Crossref
Simon G. Royce, William Dang, Gao Yuan, Jenny Tran, Assam El-Osta, Tom C. Karagiannis & Mimi L. K. Tang. (2012) Effects of the Histone Deacetylase Inhibitor, Trichostatin A, in a Chronic Allergic Airways Disease Model in Mice. Archivum Immunologiae et Therapiae Experimentalis 60:4, pages 295-306.
Crossref
Lan ZhaoChien-Nien ChenNabil HajjiEduardo OliverEmanuele CotroneoJohn WhartonDaren WangMin LiTimothy A. McKinseyKurt R. StenmarkMartin R. Wilkins. (2012) Histone Deacetylation Inhibition in Pulmonary Hypertension. Circulation 126:4, pages 455-467.
Crossref
Tom C. KaragiannisNilanjana Maulik. (2012) Factors Influencing Epigenetic Mechanisms and Related Diseases. Antioxidants & Redox Signaling 17:2, pages 192-194.
Crossref
Giuseppe GianniniWalter Cabri, Caterina Fattorusso & Manuela Rodriquez. (2012) Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Medicinal Chemistry 4:11, pages 1439-1460.
Crossref
Subathdrage D. M. Sumanadasa, Christopher D. Goodman, Andrew J. Lucke, Tina Skinner-Adams, Ishani Sahama, Ashraful Haque, Tram Anh Do, Geoffrey I. McFadden, David P. Fairlie & Katherine T. Andrews. (2012) Antimalarial Activity of the Anticancer Histone Deacetylase Inhibitor SB939. Antimicrobial Agents and Chemotherapy 56:7, pages 3849-3856.
Crossref
Simone Sidoli, Lei Cheng & Ole N. Jensen. (2012) Proteomics in chromatin biology and epigenetics: Elucidation of post-translational modifications of histone proteins by mass spectrometry. Journal of Proteomics 75:12, pages 3419-3433.
Crossref
Cheryl H. Arrowsmith, Chas Bountra, Paul V. Fish, Kevin Lee & Matthieu Schapira. (2012) Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery 11:5, pages 384-400.
Crossref
Mei-Jung Lai, Han-Li Huang, Shiow-Lin Pan, Yi-Min Liu, Chieh-Yu Peng, Hsueh-Yun Lee, Teng-Kuang Yeh, Po-Hsien Huang, Che-Ming Teng, Ching-Shih Chen, Hsun-Yueh Chuang & Jing-Ping Liou. (2012) Synthesis and Biological Evaluation of 1-Arylsulfonyl-5-( N -hydroxyacrylamide)indoles as Potent Histone Deacetylase Inhibitors with Antitumor Activity in Vivo . Journal of Medicinal Chemistry 55:8, pages 3777-3791.
Crossref
Angie Yeung, Rishi K. Bhargava, Raphael Ahn, Sarra Bahna, Na Hyea Kang, Ayush Lacoul & Lennard P. Niles. (2012) HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation. Biomedicine & Pharmacotherapy 66:3, pages 232-236.
Crossref
Simon G. Royce, Katherine Ververis & Tom C. Karagiannis. (2012) Controversies Surrounding the Potential Use of Histone Deacetylase Inhibitors for the Treatment of Asthma. ISRN Pulmonology 2012, pages 1-10.
Crossref
Matthew T. Riolo, Zachary A. Cooper, Michael P. Holloway, Yan Cheng, Cesario Bianchi, Evgeny Yakirevich, Li Ma, Y. Eugene Chin & Rachel A. Altura. (2012) Histone Deacetylase 6 (HDAC6) Deacetylates Survivin for Its Nuclear Export in Breast Cancer. Journal of Biological Chemistry 287:14, pages 10885-10893.
Crossref
Timothy A. McKinsey. (2012) Therapeutic Potential for HDAC Inhibitors in the Heart. Annual Review of Pharmacology and Toxicology 52:1, pages 303-319.
Crossref
S Spiegel, S Milstien & S Grant. (2011) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31:5, pages 537-551.
Crossref
Mark F. McCarty. (2012) Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. Medical Hypotheses 78:2, pages 262-269.
Crossref
Marisa Meyers‐Needham, Suriyan Ponnusamy, Salih Gencer, Wenhui Jiang, Raquela J. Thomas, Can E. Senkal & Besim Ogretmen. (2011) Concerted functions of HDAC1 and microRNA‐574‐5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells . EMBO Molecular Medicine 4:2, pages 78-92.
Crossref
Katherine Ververis & Tom C. Karagiannis. (2012) Overview of the Classical Histone Deacetylase Enzymes and Histone Deacetylase Inhibitors. ISRN Cell Biology 2012, pages 1-12.
Crossref
John Spencer, Jahangir Amin, Ramesh Boddiboyena, Graham Packham, Breeze E. Cavell, Sharifah S. Syed Alwi, Ronald M. Paranal, Tom D. Heightman, Minghua Wang, Brian Marsden, Peter Coxhead, Matthew Guille, Graham J. Tizzard, Simon J. Coles & James E. Bradner.. (2012) Click JAHAs: conformationally restricted ferrocene-based histone deacetylase inhibitors. MedChemComm 3:1, pages 61-64.
Crossref

Displaying 200 of 222 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.